Quantum Health Sets New Standard for Transparency and Value in Healthcare Navigation Amid Growing Employer Concerns About Escalating Costs
DUBLIN, Ohio--(BUSINESS WIRE)--Jun 30, 2025--
Quantum Health, the creator of healthcare navigation, today announced the launch of its new comprehensive intervention and value reporting capability, Action to Impact, which proves – at the member level – how its healthcare navigation model reduces costs, improves outcomes and enhances employee experience. Powered by a dynamic AI engine and 25 years of proprietary data, Action to Impact provides transparent, actionable evidence, connecting specific navigation actions to quantifiable results.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250630761431/en/
This launch comes at a time when self-insured employers are demanding more from their healthcare and benefits investments. According to the newly released State of Healthcare Survey 2025: The Transformative Power of Trust in Healthcare by Arizent and Employee Benefit News (EBN), sponsored by Quantum Health, 79% of employers identified company cost as the top concern they are focused on addressing in their latest annual benefits cycle.
While these value-driving interactions have long been part of Quantum's model, Action to Impact offers a new way to package and share insights with clients and consultants, while giving internal teams real-time feedback for continuous improvement. The solution connects every touchpoint, from navigation and steerage to clinical support, continuously optimizing member and provider experiences to improve clinical, financial and satisfaction outcomes. By transforming traditional ROI into specific, actionable insights, Quantum Health proves the value of its interventions for each client.
'Proving our ability to drive better outcomes at a lower cost has never been more essential. Today's clients expect more than anecdotes — they demand data-driven answers to their most pressing questions,' said Chris Reed, Director of Value Creation at Quantum Health. 'Employers want specifics: What actions were taken? What actually worked? With Action to Impact, Quantum Health delivers those answers through advanced analytics that quantify how navigation interventions reduce costs and improve outcomes.'
At the heart of Quantum Health's approach is its proprietary Real-Time Intercept® (RTI) platform, which enables member engagement an average of 110 days before the first claim — often before costs or complexity escalate. These early 'value moments' offer critical opportunities to influence care decisions and outcomes, allowing Quantum Health clients to achieve better health and financial results through meaningful, proactive engagement. These results are independently validated by MorningStar Actuarial Consulting, whose study of 2018-2022 claims data finds that Quantum Health's navigation and care coordination solution produces substantial and steadily accumulating ROI.
Why This Matters —
Self-insured employers are under pressure to do more with less – and prove it. As HR teams seek to optimize every dollar spent, Quantum Health's Action to Impact analytics deliver the insight needed to rise to that challenge.
'Trust is a key part of the value equation for employees,' said Kerry Gross, Director of Research Intelligence at Arizent. 'Those who trust that the entities supporting their care have their best interests in mind are more likely to get preventive primary care and more likely to be satisfied with their overall wellness offerings.'
Employers are turning to data to guide their healthcare decisions. The EBN State of Healthcare survey indicates that utilization data (88%) and insurance claims data (84%) are reported as the most trusted sources. Meanwhile, 53% of employers say they are confident their navigation partner can demonstrate how member engagement translates into cost savings. Still, just under half are only somewhat or slightly confident that engagement and cost savings data is being clearly tied together.
'We don't just show engagement metrics — we connect them to real savings, better care and improved member experiences,' added Reed. 'Our enhanced reporting pinpoints the most complex journeys, identifies where the greatest value is created, and outlines next steps to maximize results. As our dataset matures, insights become even more predictive, helping clients stay ahead of emerging challenges.'
To explore the full results of the 2025 State of Healthcare study, visit benefitnews.com.
About Employee Benefit News Employee Benefit News (EBN) is the leading media resource for decision-makers in employee benefits, HR, and workplace culture. EBN provides critical insights to help business leaders navigate shifting industry dynamics, reduce care costs, improve retirement plans, and build diverse, high-performing workforces. Learn more at www.benefitnews.com.
About Arizent Research Arizent delivers actionable insights through full-service research solutions powered by first-party data, expert perspectives, and engaged professional communities. Its portfolio includes trusted brands across financial services and professional sectors, such as American Banker, Financial Planning, Accounting Today, and Employee Benefit News. For more, visit www.arizent.com.
About Quantum Health Celebrating 25 years of innovation, Quantum Health is a leading consumer healthcare navigation and care coordination company. Its Real-Time Intercept® platform identifies early intervention opportunities to improve engagement, outcomes, and cost efficiency. Based in Dublin, Ohio, Quantum Health has earned national recognition for growth and workplace culture, including honors from FORTUNE, Inc. 5000, and the Women Presidents' Organization.
To learn more, visit www.Quantum-Health.com and connect on LinkedIn.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250630761431/en/
CONTACT: Media Contact:Alison Travis
Corporate Communications, Quantum Health
[email protected]
220-465-9386
KEYWORD: UNITED STATES NORTH AMERICA OHIO
INDUSTRY KEYWORD: OTHER PROFESSIONAL SERVICES INSURANCE DATA ANALYTICS HUMAN RESOURCES HEALTH PROFESSIONAL SERVICES HEALTH INSURANCE OTHER HEALTH
SOURCE: Quantum Health
Copyright Business Wire 2025.
PUB: 06/30/2025 08:15 AM/DISC: 06/30/2025 08:15 AM
http://www.businesswire.com/news/home/20250630761431/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
42 minutes ago
- Business Wire
Bay Psychiatric Associates Hosts Open House for Healthcare Providers
SAN MATEO, Calif.--(BUSINESS WIRE)--Bay Psychiatric Associates is excited to announce a successful Open House event at its newly expanded San Mateo location, held on Wednesday, May 7th, 2025. This event welcomed healthcare providers interested in learning more about the clinic's comprehensive mental health services, including Ketamine/Spravato, Transcranial Magnetic Stimulation (TMS), and Outpatient Services such as Psychotherapy and Medication Management. We're thrilled to open our doors to healthcare providers in the community and share the innovative treatments we offer to help individuals manage mental health conditions. Share Founded in 1994, Bay Psychiatric Associates has long been a trusted leader in mental health care in the Bay Area. To meet the growing demand for advanced treatment options, the clinic has expanded its services. The multidisciplinary team, including psychiatrists and dedicated support staff, works collaboratively to ensure patients receive effective, accessible, and compassionate care. The Open House featured guided tours of the facility, opportunities to meet the clinic's medical and administrative staff, and an in-depth overview of the latest in psychiatric care. Hors d'oeuvres and refreshments were provided, and the event also served as a networking opportunity for local healthcare professionals to connect and discuss potential referral partnerships. 'We're thrilled to open our doors to healthcare providers in the community and share the innovative treatments we offer to help individuals manage mental health conditions,' said Dr. Roberto Estrada, Interventional Psychiatry Medical Director at Bay Psychiatric Associates. 'Our team has worked tirelessly to ensure that our services are not only effective but also accessible to those who need them most. We look forward to discussing these advancements with our colleagues in the healthcare field.' About Bay Psychiatric Associates Bay Psychiatric Associates is a leading mental health provider in the Bay Area, specializing in innovative treatments for mental health conditions, including Transcranial Magnetic Stimulation (TMS), Spravato (esketamine), and ketamine therapy. The clinic's multidisciplinary team is dedicated to providing the highest quality care to patients struggling with depression, anxiety, and other mental health disorders. Outpatient clinics are located in Berkeley, San Francisco, Corte Madera, and San Mateo. Learn more via our website.
Business Upturn
an hour ago
- Business Upturn
DRC Medicine Ltd. Announces the Business Combination Agreement with Ribbon Acquisition Corp.
Combined Company Expected to be Listed on NASDAQ Global Market DRC Medicine Ltd. ('DRC Medicine' or the 'Company'), is an innovative healthcare and biotechnology company headquartered in Japan, focused on the research, development, and commercialization of advanced medical technologies that address significant global health challenges. The Company is best known for its proprietary Hydro Silver Titanium® technology, initially applied in consumer hygiene products such as masks and towels, and now being advanced to obtain medical device certification as among the world's first therapeutic masks for seasonal allergic rhinitis. Combined company to have an implied initial pro forma equity value of approximately $422.15 Million, (assuming no redemptions) and the transaction is expected to deliver cash proceeds of around $50.42 Million to DRC Medicine (assuming no redemptions) to fund DRC Medicine's business and operations, which include devices' clinical trial and certification. Current DRC Medicine shareholders will retain 100% of their equity and will continue to own approximately 82.91% of the combined company on a pro forma basis, assuming no redemptions by Ribbon's shareholder. Tokyo, June 30, 2025 (GLOBE NEWSWIRE) — DRC Medicine Ltd., an innovative healthcare and biotechnology company based in Tokyo, Japan ('DRC' or the 'Company'), announced today that it has entered into a business combination agreement (the 'Business Combination Agreement') with Ribbon Acquisition Corp. (NASDAQ: RIBB) ('Ribbon'), a special purpose acquisition company, DRC Medicine Inc., a Delaware company limited by shares (DRC Medicine) and DRC Merger Inc. ('Merger Sub'), a Delaware company limited by shares and a directly owned subsidiary of DRC Medicine, which would result in DRC Medicine becoming a publicly-traded company (the 'Proposed Transaction'). DRC Medicine Ltd. is an innovative healthcare and biotechnology company headquartered in Japan, focused on the research, development, and commercialization of advanced medical technologies that address significant global health challenges. The Company is best known for its proprietary Hydro Silver Titanium® technology, initially applied in consumer hygiene products such as masks and towels, and now being advanced to obtain medical device certification as among the world's first therapeutic masks for seasonal allergic rhinitis. In addition to medical devices, the Company is developing a pipeline of In Vitro Diagnostic ('IVD') kits for infectious diseases and allergen detection, combining its world-only cell-free protein synthesis technology leveraging AI powered Apps and is in final negotiation in acquiring an innovative ATP-enhancing drug for Parkinson's disease drugs development company, the drug is currently in clinical trials. This diverse portfolio is driven by a strong focus on unmet medical needs, AI-assisted discovery, and global healthcare infrastructure transformation. For more information, visit and Dr. Marumi Okazaki, President & CEO of DRC, said: 'This transaction will give us the resources that will enable us to capture the positive trends in our industry. Given the growth of airborne allergens, respiratory diseases and infectious diseases, increasing demand for better respiratory protection mask and faster and a more accurate IVD kits, we intend to invest in more IVD kits paired with AI-powered Apps in achieving universal diagnostics to empower the general public in guarding their health and fight against allergen, respiratory diseases and infectious diseases as well as catapult our research and development, production capabilities to meet the rising demand for better respiratory protection mask and AI-powered IVD kits.' Mr. Angshuman (Bubai) Ghosh, Chairman/CEO of Ribbon, said, ' This business combination agreement with DRC is a great opportunity to enter into an exciting and accelerating growth healthcare and biotechnology industry. We believe its highly capable and experienced management team with all of the founders with substantial experience in developing innovative technologies, supported by their technology-savvy specialists and R&D team who are committed to pioneering innovations, will enable DRC to continuously innovate and advance their healthcare and biotechnology applications to gain a greater foothold in the global market.' Transaction Overview As a part of the Proposed Transaction, an intermediate holding company incorporated in Japan (the 'Intermediate Co.' will acquire the shares of DRC Medicine, after which the Intermediate Co. will engage in a share exchange transaction with the shareholders of the Company, such that the Company will become a wholly-owned subsidiary of Intermediate Co. and the shareholders of the Company will become shareholders of DRC Medicine (the 'DRC Restructuring'). Following the consummation of the DRC Restructuring and subject to the terms and conditions of the Business Combination Agreement, Ribbon will merge with and into the Merger Sub, with Merger Sub continuing as the surviving company and remaining a wholly owned subsidiary of DRC Medicine. The Proposed Transaction implies a pre-money equity value of US$350 million of DRC on a fully diluted basis, and is expected to provide DRC with access to approximately US$50 million cash from Ribbon's IPO proceeds held in trust, assuming no redemption by Ribbon's shareholders in connection with the current and future proxy exercises and prior to the payment of any transaction expenses. The parties will cooperate in connection with any financing arrangement the parties seek in connection with the Proposed Transaction. Advisors A.G.P./Alliance Global Partners serves as the financial advisor and lead capital markets advisor to Ribbon. Geneva Capital Group serves as the financial advisor to DRC. Celine & Partners serves as the legal advisor to Ribbon. Ross Law Group serves as the legal advisor to DRC. About DRC Medicine Ltd . Founded in 2007, DRC is an innovative healthcare and biotechnology company headquartered in Japan, focused on the research, development, and commercialization of advanced medical technologies that address significant global health challenges. The Company is best known for its proprietary Hydro Silver Titanium® technology, initially applied in consumer hygiene products such as masks and towels, and now being advanced to obtain medical device certification as among the world's first therapeutic masks for seasonal allergic rhinitis . In addition to medical devices, the Company is developing a pipeline of In Vitro Diagnostic ('IVD') kits for infectious diseases and allergen detection, combining its world-only cell-free protein synthesis technology leveraging AI powered Apps and is in final negotiation in acquiring an innovative ATP-enhancing drug for Parkinson's disease. About Ribbon Acquisition Corp . Ribbon is a blank check company whose business purpose is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. While Ribbon intends to conduct a global search for target businesses without being limited by geographic region, certain executive officers and independent directors are based in Hong Kong, and certain executive officers have experience investing in and building businesses in the Asia Pacific region and have a deep understanding of the region's business environment, regulations, regulatory bodies and culture. Ribbon will not undertake an initial business combination with any company being based in or having the majority of the company's operations in Greater China. Ribbon is led by Mr. Angshuman (Bubai) Ghosh, Ribbon's Chief Executive Officer, and Ms. Zhiyang (Anna) Zhou, Ribbon's Chief Financial Officer. Important Additional Information Regarding the Transaction Will Be Filed With the SEC This press release relates to the proposed business combination between Ribbon Acquisition Corp. and DRC Medicine Ltd.. This press release does not constitute an offer to sell or exchange, or the solicitation of an offer to buy or exchange, any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, sale or exchange would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. DRC intends to file a Registration Statement on Form S-4 with the SEC, which will include a document that serves as a joint prospectus and proxy statement, referred to as a proxy statement/prospectus. A proxy statement/prospectus will be sent to all Ribbon shareholders. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom. Ribbon and DRC will also file other documents regarding the proposed business combination with the SEC. This press release does not contain all the information that should be considered concerning the proposed business combination and is not intended to form the basis of any investment decision or any other decision in respect of the business combination. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND SECURITY HOLDERS OF RIBBON ARE URGED TO READ THE REGISTRATION STATEMENT, THE PROXY STATEMENT/PROSPECTUS AND ALL OTHER RELEVANT DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED BUSINESS COMBINATION AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED BUSINESS COMBINATION. Investors and security holders will be able to obtain free copies of the registration statement, the proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC by Ribbon and DRC through the website maintained by the SEC at The documents filed by Ribbon and DRC with the SEC also may be obtained free of charge upon written request to Ribbon Acquisition Corp., Central Park Tower LaTour Shinjuku Room 3001, 6-15-1 Nishi Shinjuku, Shinjuku-ku Tokyo 160-0023. Participants in the Solicitations Ribbon, DRC and their respective directors, executive officers, other members of management, and employees, under SEC rules, may be deemed to be participants in the solicitation of proxies from Ribbon's shareholders in connection with the proposed business combination. You can find information about Ribbon's directors and executive officers and their interest in Ribbon in Ribbon's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which was originally filed with the SEC on April 1, 2025. A list of the names of the directors, executive officers, other members of management and employees of Ribbon and DRC, as well as information regarding their interests in the business combination, will be contained in the Registration Statement on Form S-4 to be filed with the SEC by DRC. Additional information regarding the interests of such potential participants in the solicitation process may also be included in other relevant documents when they are filed with the SEC. You may obtain free copies of these documents from the sources indicated above. Caution About Forward-Looking Statements This press release may contain forward-looking statements within the meaning of section 27A of the U.S. Securities Act of 1933, as amended (the 'Securities Act'), and section 21E of the U.S. Securities Exchange Act of 1934 ('Exchange Act') that are based on beliefs and assumptions and on information currently available to Ribbon and DRC. These forward-looking statements are based on Ribbon's and DRC's expectations and beliefs concerning future events and involve risks and uncertainties that may cause actual results to differ materially from current expectations. In some cases, you can identify forward-looking statements by the following words: 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'intend,' 'plan,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'ongoing,' 'target,' 'seek' or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Any statements that refer to expectations, projections or other characterizations of future events or circumstances, including projections of market opportunity and market share, the capability of DRC's business plans including its plans to expand, the anticipated enterprise value of the combined company following the consummation of the proposed business combination, anticipated benefits of the proposed business combination and expectations related to the terms and timing of the proposed business combination, are also forward-looking statements. Although each of Ribbon and DRC believes that it has a reasonable basis for each forward-looking statement contained in this communication, each of Ribbon and DRC cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. These factors are difficult to predict accurately and may be beyond Ribbon's and DRC's control. In addition, there will be risks and uncertainties described in the proxy statement/prospectus on Form S-4 relating to the proposed business combination, which is expected to be filed by DRC with the SEC and other documents filed by Ribbon or DRC from time to time with the SEC. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those expressed or implied in the forward-looking statements. There may be additional risks that neither Ribbon or DRC presently know or that Ribbon and DRC currently believe are immaterial and that could also cause actual results to differ from those contained in the forward-looking statements. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by Ribbon or DRC, their respective directors, officers or employees or any other person that Ribbon and DRC will achieve their objectives and plans in any specified time frame, or at all. Forward-looking statements in this communication or elsewhere speak only as of the date made. New uncertainties and risks arise from time to time, and it is impossible for Ribbon or DRC to predict these events or how they may affect Ribbon or DRC. Except as required by law, neither Ribbon nor DRC has any duty to, and does not intend to, update or revise the forward-looking statements in this communication or elsewhere after the date this communication is issued. In light of these risks and uncertainties, investors should keep in mind that results, events or developments discussed in any forward-looking statement made in this communication may not occur. Uncertainties and risk factors that could affect Ribbon's and DRC's future performance and cause results to differ from the forward-looking statements in this release include, but are not limited to: the occurrence of any event, change or other circumstances that could give rise to the termination of the business combination; the outcome of any legal proceedings that may be instituted against Ribbon or DRC, the combined company or others following the announcement of the business combination; the inability to complete the business combination due to the failure to obtain approval of the shareholders of Ribbon or to satisfy other conditions to closing; changes to the proposed structure of the business combination that may be required or appropriate as a result of applicable laws or regulations; the ability to meet stock exchange listing standards following the consummation of the business combination; the risk that the business combination disrupts current plans and operations of Ribbon or DRC as a result of the announcement and consummation of the business combination; the ability to recognize the anticipated benefits of the business combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain relationships with customers and retain its management and key employees; costs related to the business combination; changes in applicable laws or regulations; Ribbon's estimates of expenditures and profitability and underlying assumptions with respect to shareholder redemptions and purchase price and other adjustments; the impact of the COVID-19 pandemic; changes in laws and regulations that impact DRC; ability to enforce, protect and maintain intellectual property rights; and other risks and uncertainties set forth in the section entitled 'Risk Factors' and 'Cautionary Note Regarding Forward-Looking Statements' in Ribbon's final prospectus dated January 14, 2025 relating to its initial public offering and in subsequent filings with the SEC, including the registration statement on Form S-4 relating to the business combination expected to be filed by DRC. No Offer or Solicitation This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act, or an exemption therefrom. For further queries please contact: Geneva Capital Group on behalf of DRC Bob Lau, [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Business Wire
2 hours ago
- Business Wire
Resecurity Appoints Luiz Cota as Territory Manager for Brazil
LOS ANGELES--(BUSINESS WIRE)-- Resecurity, Inc., a global leader in cybersecurity and threat intelligence solutions, is pleased to announce the appointment of Luiz Cota as Territory Manager for Brazil. With more than three decades of experience in technology and cybersecurity across Latin America, Cota will spearhead Resecurity's efforts to expand its footprint in Brazil and strengthen cyber defense capabilities for local enterprises, public institutions, and critical infrastructure. Throughout his career, Luiz Cota has held senior roles at leading cybersecurity and technology firms including Cisco, IronPort, SurfControl, Fidelis, and Offensive Security. His extensive background in both commercial and technical domains positions him to effectively adapt and deliver Resecurity's advanced threat intelligence solutions to meet the unique needs of the Brazilian market. Cota brings a rare combination of deep technical expertise and strategic business insight. He founded Brazil's first cyber-insurance brokerage, advising startups and established enterprises on cyber risk mitigation, threat modeling, and digital resilience. With a clear understanding of Brazil's regulatory framework, digital economy, and emerging threat landscape, he is uniquely equipped to help organizations implement localized, intelligence-driven cybersecurity strategies. 'Luiz offers a profound understanding of the Brazilian cybersecurity landscape and a proven ability to execute complex go-to-market strategies,' said Gene Yoo, CEO of Resecurity. 'His leadership will be key as we accelerate our growth in Latin America and support Brazilian organizations in building stronger defenses against rapidly evolving cyber threats.' Luiz Cota holds a degree in Electronic Engineering, a specialization in marketing, and an MBA, enabling him to bridge the gap between technical innovation and business execution. He will lead Resecurity's regional initiatives in partnership development, threat intelligence delivery, and customer success, with a focus on empowering local partners and clients to anticipate, detect, and respond to cyber risks with greater precision. 'Cybersecurity has become a strategic priority in Brazil as digital transformation advances across all sectors,' said Luiz Cota. 'I'm excited to join Resecurity and bring world-class cyber intelligence capabilities to organizations committed to protecting their data, infrastructure, and people.' This appointment marks a significant step in Resecurity's regional expansion strategy, reinforcing its commitment to providing scalable, proactive, and locally relevant cybersecurity solutions throughout Latin America. About Resecurity Resecurity® is a cybersecurity company that delivers a unified endpoint protection, fraud prevention, risk management, and cyber threat intelligence platform. Known for providing best-of-breed data-driven intelligence solutions, Resecurity's services and platforms focus on early-warning identification of data breaches and comprehensive protection against cybersecurity risks. Founded in 2016, it has been globally recognized as one of the world's most innovative cybersecurity companies with the sole mission of enabling organizations to combat cyber threats regardless of how sophisticated they are. Most recently, by Inc. Magazine, Resecurity was named one of the Top 10 fastest-growing private cybersecurity companies in Los Angeles, California. As a member of InfraGard National Members Alliance (INMA), AFCEA, NDIA, SIA, FS-ISAC, and the American Chamber of Commerce in Saudi Arabia (AmChamKSA), Singapore (AmChamSG), Korea (AmChamKorea), Mexico (AmChamMX), Thailand (AmChamThailand), and UAE (AmChamDubai). To learn more about Resecurity, visit
